Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WAT
WAT logo

WAT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
360.650
Open
358.970
VWAP
356.55
Vol
1.46M
Mkt Cap
34.90B
Low
353.560
Amount
520.84M
EV/EBITDA(TTM)
37.40
Total Shares
98.19M
EV
39.65B
EV/OCF(TTM)
101.67
P/S(TTM)
6.16
Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.
Show More

Events Timeline

(ET)
2026-06-03
08:10:00
Waters BD BACTEC FXI System Receives FDA 510(k) Clearance
select

News

PRnewswire
5.0
06-09PRnewswire
Waters Launches Innovative Battery Safety Testing Instrument
  • Battery Safety Testing Revolution: Waters Corporation's Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-consuming preparation steps, thereby accelerating testing speed and providing more detailed safety and performance insights.
  • Multidimensional Data Capture: This instrument is the only DSC that simultaneously captures thermal, evolved gas, and electrochemical performance data, helping researchers identify thermal runaway and battery failures earlier, enhancing safety in battery development.
  • Significant Reduction in Preparation Time: The new capsule design reduces sample preparation time by over 90%, preserving sample integrity while significantly accelerating data generation and optimizing experimental workflows.
  • Broad Application Prospects: With a temperature range of -80°C to 600°C, the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, advancing early-stage battery safety research and reducing development risks.
PRnewswire
5.0
06-08PRnewswire
Waters Launches Innovative BioResolve and GTxResolve Columns for Biopharmaceuticals
  • Product Launch: Waters Corporation has introduced the BioResolve™ Peptide and GTxResolve™ Lipid Columns, specifically designed to address the challenge of separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles, thereby enhancing the safety and efficacy of drug development.
  • Market Demand Response: The new columns significantly improve separation efficiency and speed, helping pharmaceutical companies reduce time to market, enhance regulatory confidence, and lower patient safety risks associated with impurities.
  • Technical Advantages: The BioResolve and GTxResolve Columns utilize specially designed surface chemistries and superficially porous particles to ensure consistent performance across U(H)PLC and HPLC systems, suitable for all stages from early research to manufacturing.
  • Positive Customer Feedback: Researchers from Alembic Pharmaceuticals and Acuitas Therapeutics have expressed high satisfaction with the new products' separation performance, stating that they can meet current and future regulatory requirements while facilitating rapid analysis of complex peptides and lipids.
NASDAQ.COM
9.0
06-03NASDAQ.COM
Waters Corporation Receives FDA Clearance for Next-Gen Blood Culture System
  • FDA Clearance: Waters Corporation announced that its BD BACTEC FXI Culture System has received 510(k) clearance from the FDA, marking a significant technological advancement in bloodstream infection diagnostics and is expected to enhance market competitiveness.
  • Automation Enhancement: The system features fully automated vial loading, unloading, incubation, and detection alerts, capable of loading up to 60 vials at a time, which is a 50% increase over the leading competing system, thereby significantly improving laboratory efficiency.
  • Reduced Detection Time: Clinical study data indicates that the BD BACTEC FXI system reduces the mean time to detection by approximately three hours compared to the previous-generation BD BACTEC FX Blood Culture System, which will accelerate infection diagnosis and improve patient treatment timing.
  • Stock Performance: Despite the FDA clearance for the new system, Waters Corporation's shares closed at $371.93 on Tuesday, down 1.65%, indicating a relatively muted market reaction to the news.
Newsfilter
5.0
06-03Newsfilter
FDA Approves BD BACTEC FXI Culture System for U.S. Market
  • Reduced Detection Time: The BD BACTEC FXI Culture System achieves a mean time to detection that is approximately three hours faster (about 15% reduction) than its predecessor, significantly enhancing early pathogen identification and timely antimicrobial therapy, which is crucial for reducing mortality rates.
  • Enhanced Automation: This system features an industry-leading automated loading capacity of up to 960 vials, which maximizes laboratory efficiency by minimizing manual intervention and increasing staff walk-away time, thereby streamlining workflow in high-throughput microbiology labs.
  • International Certification Expansion: The BD BACTEC FXI Culture System has received CE marking and licensing from Japan's PMDA, indicating its availability in European and Japanese markets, which strengthens its competitive position globally.
  • Significant Clinical Impact: Rapid laboratory results are critical for timely clinical decisions, especially in acute care settings, where each hour of delayed treatment can increase mortality by 3.6% to 9.9%, underscoring the system's importance in modern microbiology laboratories.
NASDAQ.COM
7.5
06-02NASDAQ.COM
Market Capitalization Comparison: Steel Dynamics vs. Waters Corp.
  • Market Cap Comparison: Steel Dynamics Inc. (STLD) has a market capitalization of $37.72 billion, compared to Waters Corp. (WAT) at $37.13 billion, highlighting the relative value differences that can influence investor decisions and capital flows.
  • Investor Misconception: Many novice investors mistakenly compare stock prices to gauge company value, but market capitalization provides a more accurate assessment of company size, enabling smarter investment choices.
  • Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs may invest in these stocks, thereby influencing their liquidity and market performance.
  • Stock Performance: At Tuesday's close, STLD shares rose approximately 3.8%, while WAT shares fell about 1.6%, reflecting differing market expectations for the future performance of the two companies.
PRnewswire
5.0
06-01PRnewswire
Waters Launches New Cyclic IMS P20 Mass Spectrometer
  • Technological Innovation: The launch of the Cyclic IMS P20 Mass Spectrometer by Waters Corporation features over a 10-fold increase in MS/MS sensitivity, significantly enhancing the analysis of low-abundance molecules, thereby accelerating research into disease mechanisms and drug development.
  • Integrated Functionality: This instrument combines MALDI and DESI imaging sources, providing a more comprehensive molecular view that helps researchers observe small molecules, lipids, peptides, and proteins more clearly in samples, facilitating biomarker identification.
  • Market Launch: The Cyclic IMS P20 Mass Spectrometer is expected to be available globally in September 2026, marking Waters' ongoing innovation in the life sciences sector and enabling scientists to discover and develop new therapies more rapidly.
  • Growing Market Demand: As researchers pursue larger and more heterogeneous therapeutic targets, the high sensitivity and structural resolution of this instrument meet the needs of modern analytical workflows, further solidifying Waters' leadership position in the analytical technology market.
Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
Wall Street analysts forecast WAT stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
350.00
Averages
414.08
High
480.00
Current: 0.000
sliders
Low
350.00
Averages
414.08
High
480.00
Piper Sandler
Neutral
initiated
$400
AI Analysis
2026-06-11
Reason
Piper Sandler
Price Target
$400
AI Analysis
2026-06-11
initiated
Neutral
Reason
Piper Sandler initiated coverage of Waters with a Neutral rating and $400 price target. The firm launched coverage of the life science tools sector with a \"feet in the shallow end of the pool\" approach. Piper only recommends buying Twist Bioscience for its growing exposure to next generation drug discovery and development. Headwinds for the group faces from biotech and academic spending as well as China exposure will likely improve near term, the analyst tells investors in a research note. However, Piper wants to see some of the next big growth drivers materialize before recommending more of the stocks. Investors \"can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-Covid,\" the firm contends.
HSBC
Buy
maintain
$415 -> $435
2026-06-03
Reason
HSBC
Price Target
$415 -> $435
2026-06-03
maintain
Buy
Reason
HSBC raised the firm's price target on Waters to $435 from $415 and keeps a Buy rating on the shares. The firm says market expectations on life science tools "remain bearish" with allocation tilted towards managed care and therapeutics within healthcare. While the tools sector is priced for disappointment, HSBC sees "green shoots of recovery," notably in bioprocessing and quality assurance, the analyst tells investors in a research note. The firm adjusted target prices to reflect risk-adjusted return expectations. HSBC's preferred ideas are Waters, Iqvia, and Sartorius.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WAT
Unlock Now

Valuation Metrics

The current forward P/E ratio for Waters Corp (WAT.N) is 24.63, compared to its 5-year average forward P/E of 26.32. For a more detailed relative valuation and DCF analysis to assess Waters Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.32
Current PE
24.63
Overvalued PE
30.40
Undervalued PE
22.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.29
Current EV/EBITDA
70.71
Overvalued EV/EBITDA
28.86
Undervalued EV/EBITDA
11.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
6.30
Current PS
4.91
Overvalued PS
7.42
Undervalued PS
5.19

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

us stock market
Intellectia · 55 candidates
Relative Vol: >= 1.20Moving Average Relationship: PriceAboveMA20, PriceAboveMA5Is Optionable: TrueIs Index Component: GSPC, NDX, DJIOne Day Predict Return: >= 0.0%One Week Predict Return: >= 0.0%Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
NTAP logo
NTAP
NetApp Inc
34.39B
TEAM logo
TEAM
Atlassian Corp
27.31B
NOW logo
NOW
ServiceNow Inc
128.26B
IBM logo
IBM
International Business Machines Corp
279.90B
WDAY logo
WDAY
Workday Inc
36.11B
PANW logo
PANW
Palo Alto Networks Inc
229.86B
give me best stocks to night trade tonight
Intellectia · 84 candidates
Market Cap: >= 500.00MVolume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Is Optionable: TrueMonthly Average Dollar Volume: >= 300,000News Driver: Positive
Ticker
Name
Market Cap$
top bottom
EVER logo
EVER
EverQuote Inc
842.59M
STRL logo
STRL
Sterling Infrastructure Inc
24.73B
DOCN logo
DOCN
DigitalOcean Holdings Inc
15.94B
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
BLDP logo
BLDP
Ballard Power Systems Inc
1.31B
IART logo
IART
Integra Lifesciences Holdings Corp
1.03B
buy or hold
Intellectia · 100 candidates
Price: >= $-100.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Ema 60: >= -100Macd: positiveNews Driver: Positive
Ticker
Name
Market Cap$
top bottom
BDSX logo
BDSX
Biodesix Inc
113.91M
CIFR logo
CIFR
Cipher Digital Inc
7.26B
LIND logo
LIND
Lindblad Expeditions Holdings Inc
1.17B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.51B
PLOW logo
PLOW
Douglas Dynamics Inc
1.03B
WAT logo
WAT
Waters Corp
29.63B
highest return likely tomorrow
Intellectia · 67 candidates
Market Cap: >= 300.00MPrice: $2.00 - $500.00One Day Rise Prob: >= 55One Day Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
9.24B
BTSG logo
BTSG
Brightspring Health Services Inc
8.09B
RDW logo
RDW
Redwire Corp
1.94B
SY logo
SY
So-Young International Inc
332.79M
SNCY logo
SNCY
Sun Country Airlines Holdings Inc
874.99M
CLS logo
CLS
Celestica Inc
32.42B
which stock is going to skyrocket tomorrow
Intellectia · 41 candidates
Rsi Category: moderateRelative Vol: >= 1.20Analyst Action: UpgradeMoving Average Relationship: PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
BMA logo
BMA
Banco Macro SA
6.27B
HRI logo
HRI
Herc Holdings Inc
5.48B
CINT logo
CINT
Ci&T Inc
608.04M
RNGR logo
RNGR
Ranger Energy Services Inc
354.89M
RXRX logo
RXRX
Recursion Pharmaceuticals Inc
2.40B
LTH logo
LTH
Life Time Group Holdings Inc
6.15B

Whales Holding WAT

R
RobecoSAM AG
Holding
WAT
+26.64%
3M Return
L
Logan Capital Management, Inc.
Holding
WAT
+19.22%
3M Return
F
Freemont Capital Pte. Ltd.
Holding
WAT
+13.84%
3M Return
M
Motley Fool Asset Management, LLC
Holding
WAT
+13.71%
3M Return
B
BLI - Banque De Luxembourg Investments S.A.
Holding
WAT
+11.25%
3M Return
T
The London Company of Virginia, LLC
Holding
WAT
+10.47%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Waters Corp (WAT) stock price today?

The current price of WAT is 355.44 USD — it has decreased -0.44

What is Waters Corp (WAT)'s business?

Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

What is the price predicton of WAT Stock?

Wall Street analysts forecast WAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WAT is414.08 USD with a low forecast of 350.00 USD and a high forecast of 480.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Waters Corp (WAT)'s revenue for the last quarter?

Waters Corp revenue for the last quarter amounts to 1.27B USD, increased 91.48

What is Waters Corp (WAT)'s earnings per share (EPS) for the last quarter?

Waters Corp. EPS for the last quarter amounts to -0.88 USD, decreased -143.35

How many employees does Waters Corp (WAT). have?

Waters Corp (WAT) has 7900 emplpoyees as of June 21 2026.

What is Waters Corp (WAT) market cap?

Today WAT has the market capitalization of 34.90B USD.